Treatment
chimeric antigen receptor gene modified T cells clinical trials
We’re tracking 12 recruiting studies that include chimeric antigen receptor gene modified T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07751380RecruitingPhase 1
CAR T-cell therapy for children and young adults with certain sarcomas
This trial tests a new kind of cell therapy called CAR T-cells that are engineered to find and attack sarcoma cells carrying a marker called B7-H3. It is for children and young adults whose sarcoma has come back or not gone away after treatment.
LondonAges 1–24 - NCT05562024RecruitingPhase 1
Study drug for B7-H3 positive neuroblastoma after relapse
This Phase 1 study tests TAA06, an injection that targets a marker called B7-H3 on neuroblastoma tumor cells. It is for children who have neuroblastoma that has come back or did not respond to prior treatment, aiming to see whether the treatment is safe and can shrink tumors.
Jinan, ShandongAges 1 year+ - NCT06609928RecruitingPhase 1
CAR T cell therapy for children with relapsed AML that has FOLR1
This trial tests a special immune cell treatment (CAR T cells) that target a protein called FOLR1 found on some AML cells. It is for children aged 6 or younger whose leukemia has come back or not responded to treatment.
Seattle, WashingtonAges Up to 6 years - NCT07188610RecruitingPhase 2
CAR-T therapy for CD7-positive T-cell leukemia or lymphoma
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
Hefei, AnhuiAges 18 years+ - NCT07297667RecruitingPhase 1
CAR T-cell therapy for GPNMB-positive solid tumours
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Calgary, AlbertaAges 15 years+ - NCT05060796RecruitingEarly Phase 1
CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
GuangzhouAges 18–75 - NCT06138132RecruitingPhase 1
CAR-T cell therapy for progressive multiple sclerosis
This trial is testing a type of immunotherapy called CAR-T cells (made from your own immune cells) to see if it can help slow or stop progressive multiple sclerosis. It is a very early safety study, so only people with progressive MS who meet strict health criteria can join.
Palo Alto, CaliforniaAges 18–65 - NCT06783816Recruiting
New immune cell therapy for blood cancers
This study tests a new type of CAR-T cell therapy designed to treat certain blood cancers (like leukemia, lymphoma, or multiple myeloma) that have come back or not responded to standard treatment. The cells are enhanced with IL-15 to help them work better.
Taiyuan, ShanxiAges Any age - NCT06850285Recruiting
CD30 CAR-T for relapsed or refractory CD30+ lymphoma
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
Taiyuan, ShangxiAges 15–80 - NCT06865664RecruitingPhase 1
Engineered immune cells for relapsed rhabdomyosarcoma in youth
This early-phase trial tests a new immune cell therapy (CAR T cells) for children and young adults whose rhabdomyosarcoma has returned or not responded to standard treatments. The goal is to see if these specially engineered cells can find and attack the cancer.
Bethesda, MarylandAges 3–39 - NCT07248176Recruiting
Universal CAR-T therapy for multiple myeloma
This trial tests a universal CAR-T cell therapy (made from donated cells) for multiple myeloma that has come back after at least two prior treatments. It may be an option if your cancer cells have a specific marker called BCMA and you have not had certain prior therapies.
ShanghaiAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+
What chimeric antigen receptor gene modified T cells is being studied for
Conditions with recruiting chimeric antigen receptor gene modified T cells studies.
Common questions
- Are there clinical trials studying chimeric antigen receptor gene modified T cells?
- Yes. Clin2 currently lists 12 recruiting studies that include chimeric antigen receptor gene modified T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a chimeric antigen receptor gene modified T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is chimeric antigen receptor gene modified T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether chimeric antigen receptor gene modified T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.